Efficacy of Matrifen in Patients Older Than 18 Years With Severe, Chronic Pain
CompletedNCT00556270
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
The aim of the study is to evaluate the efficacy and safety of matrifen in patients with severe and chronic pain who can only be sufficiently treated with opioid analgesics (WHO class 3).
Study details
- Official title
- Matrifen for Therapy of Severe, Chronic Pain.
- Conditions
- Severe, Chronic Pain
- Interventions
- Drug: Matrifen
- Sponsor
- Nycomed
- Start date
- 2007-11
- Sex
- All
- Age range
- from 18 Years
- Results posted
- No results posted in this snapshot
- Countries
- Germany
- Total sites listed
- 815
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Main inclusion criteria: * Patients with severe, chronic pain Main exclusion criteria: * Hypersensitivity of fentanyl * Co-administration of monoaminooxidase-inhibitors * Pregnancy * Respiratory depression * Chronic obstructive pulmonary disease (COPD) * Drug abuse * Impairment of CNS functions * Other criteria as defined in the Summary of Product Characteristics (Fachinformation Chapter 4.3)
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT00556270